Shares of AIM ImmunoTech Inc. (AIM) are rising above 13% in pre-market today, extending the 190.48% rally in the previous session. We alerted readers to this stock yesterday at $3.34. The stock ran up to $7.11 yesterday and closed Monday's trade at $6.10, up $4.00 or 190.48%.
On March 9, the immuno-pharma company announced that the National Institute of Infectious Diseases or NIID in Japan will begin testing AIM's drug Ampligen as a potential treatment for COVID-19, the new coronavirus infectious disease caused by SARS-CoV-2.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.